Capricor Therapeutics CAPR Noncash Lease Expenses
Noncash Lease Expenses at other companies
Other financials
Where this comes from
Reported directly by Capricor Therapeutics in its filing.
Tagged under the XBRL concept capr:NoncashLeaseExpenses.
The official record: Capricor Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Capricor Therapeutics's noncash lease expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Capricor Therapeutics's noncash lease expenses?
- Capricor Therapeutics (CAPR) reported noncash lease expenses of $641.29K in Q1 2026.
- How has Capricor Therapeutics's noncash lease expenses changed year-over-year?
- Capricor Therapeutics's noncash lease expenses increased by 3907.2% year-over-year, from -$16.84K to $641.29K.
- What is the long-term trend for Capricor Therapeutics's noncash lease expenses?
- Over 4 years (2021 to 2025), Capricor Therapeutics's noncash lease expenses has grown at a 96.1% compound annual growth rate (CAGR), from $48.4K to $715.46K.
- What does noncash lease expenses mean?
- This represents the portion of lease-related expenses that do not involve an immediate cash outflow, typically reflecting the amortization of right-of-use assets. It is added back to net income to reconcile accounting profit with actual cash generated from operations. Monitoring this helps investors distinguish between operational accounting charges and actual cash burn.